Haemate P (Human Von Willebrand Factor)

Haemate P is indicated for the management of bleeding associated with von Willebrand disease and related conditions.

• Treatment of all types of von Willebrand disease (type 1, 2, and 3) to control acute bleeding episodes.
• Prophylactic administration to prevent recurrent bleeding in patients with von Willebrand disease.
• Management of surgical or invasive procedure‑related bleeding in patients with von Willebrand disease.
• Treatment of hemophilia A patients who have low von Willebrand factor levels and require factor VIII stabilization.
• Use in pediatric and adult patients under the direction of a hematology specialist.

Adverse reactions to Haemate P have been reported, ranging from mild infusion‑related events to rare serious complications.

Common

• Headache
• Nausea or vomiting
• Fever or chills
• Mild infusion site reactions such as erythema or swelling

Serious

• Allergic reactions including urticaria, angioedema, or anaphylaxis
• Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism
• Development of inhibitors to von Willebrand factor
• Hemolytic reactions or severe hypotension

When prescribing Haemate P, clinicians should consider several safety precautions to minimize risk.

• Assess patient history for previous allergic reactions to plasma‑derived products.
• Monitor for signs of thrombosis, especially in patients with cardiovascular risk factors.
• Use caution in patients with liver disease or impaired renal function.
• Evaluate for the presence of inhibitors to von Willebrand factor before initiating therapy.
• Ensure appropriate dosing and infusion rate to reduce infusion‑related reactions.
• Pregnant or breastfeeding patients should be managed only if the potential benefit outweighs uncertain risks.

Haemate P may interact with other medications; awareness of potential interactions helps ensure safe use.

Avoid

• Concomitant use of other plasma‑derived clotting factor concentrates unless specifically indicated.
• Administration with high‑dose aspirin or other non‑steroidal anti‑inflammatory drugs that increase bleeding risk.

Use with caution

• Antifibrinolytic agents such as tranexamic acid, which may enhance hemostatic effect.
• Hormonal contraceptives or hormone replacement therapy that may affect clotting balance.
• Heparin or low‑molecular‑weight heparin, requiring close monitoring of coagulation parameters.